This website contains information about
INBRIJA® (levodopa inhalation powder)
M-INB-UK-0047
Date of preparation: December 2025
For OFF episodes in Parkinson’s Disease
INBRIJA® is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease treated with a levodopa/dopa-decarboxylase inhibitor.1
Helping them take
charge of the moment
Inhaled levodopa, on-demand:
Supporting patients when needed,
up to 5 times per day1,2
With INBRIJA® your patients can take charge when symptoms return
INBRIJA® complements baseline therapy, improving symptoms when needed1
-
Rapid
Observed relief in as little as 10 minutes2,3
-
Reliable
Pulmonary route avoids variability caused by GI tract absorption4
-
ON-DEMAND
Supporting patients when needed, up to 5 times per day1,4
GI; Gastrointestinal.
References:
- 1. INBRIJA Summary of Product Characteristics.
- 2. LeWitt PA, Hauser RA, Pahwa R, et al; SPAN-PD Study Investigators. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2019;18:145-154.
3. Isaacson SH, Pagan FL, Lew MF, Pahwa R. Should “on-demand” treatments for Parkinson’s disease OFF episodes be used earlier? Clin Park Relat Disord. 2022;7:100161.- 4. Safirstein BE, Ellenbogen A, Zhao P, Henney HR 3rd, Kegler-Ebo DM, Oh C. Pharmacokinetics of inhaled levodopa administered with oral carbidopa in the fed state in patients with Parkinson’s disease. Clin Ther. 2020;42:1034-1046.